MedTrace Logo

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

NCT07229586 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-19

No results posted yet for this study

Summary

This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Conditions

Interventions

DRUG

SHR-7367 Injection

SHR-7367 injection.

DRUG

SHR-1316 Injection

SHR-1316 injection.

DRUG

Paclitaxel for Injection

Paclitaxel for injection (Albumin Bound).

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for injection.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07229586 on ClinicalTrials.gov